Identification Of Baseline Characteristics That Predict Good Outcome Of Allogeneic Hematopoietic Cell Transplantation In Young Chronic Lymphocytic Leukemia Patients - A Retrospective Analysis From The Chronic Malignancies Working Party Of The European Society For Blood And Marrow Transplantation

Patients with relapsed/refractory chronic lymphocytic leukemia (CLL) have excellent responses with kinase or BCL2 inhibitors, but patients with high risk cytogenetics (del(17p) and/or del(11q)) do not seem to achieve long-term disease control. Allogeneic hematopoietic stem cell transplantation (alloHCT) can result in sustained progression-free survival. As non-relapse mortality (NRM) after alloHCT is partly age-dependent, alloHCT is preferably considered in younger high cytogenetic risk CLL patients, but data of early NRM and longer-term PFS lack for this age group. We focused in this study on younger allo-transplanted CLL patients ( Disclosures Dreger: Novartis: Speakers Bureau; Gilead: Speakers Bureau; Janssen: Consultancy; Novartis: Consultancy; Gilead: Consultancy; Roche: Consultancy. Gramatzki: Janssen: Other: Travel/Accommodation/Expenses, Research Funding. Delgado: Janssen: Consultancy, Honoraria; Novartis/GSK: Consultancy, Honoraria; Gilead: Consultancy, Honoraria; Roche: Consultancy, Honoraria, Research Funding; Infinity: Research Funding. Schoenland: Jansen: Honoraria, Other: financial support of conference participation, Research Funding; Prothena: Honoraria, Membership on an entity9s Board of Directors or advisory committees, Research Funding; GSK: Honoraria, Membership on an entity9s Board of Directors or advisory committees, Research Funding. Schetelig: Sanofi: Honoraria.